2025 ISAKOS Biennial Congress ePoster
A Comparative Study On Arthroscopic Superior Capsule Reconstruction Using Fascia Lata Autograft With And Without Biceps Tendon Augmentation: Two-Year Patient-Reported Outcomes And Radiographic Analysis
Kung Tseng Hung, MD, New Taipei City TAIWAN
You Hung Cheng TAIWAN
Joe Chih-Hao Chiu, MD, PhD, Gueishan District, Taoyuan City TAIWAN
Chris Hsu, Prof., Taoyuan TAIWAN
Yi-Sheng Chan, MD, Prof., Keelung, Taiwan TAIWAN
Alvin Chao-Yu Chen, Prof, Taoyuan TAIWAN
Chang Gung Memorial Hospital, Guishan District , Taoyuan City, TAIWAN
FDA Status Cleared
Summary
There was no significant difference in patient-reported outcomes between isolated and augmented SCR groups; however, the biceps tendon-augmented SCR group had more patients achieving maximal outcome improvement for ASES score and slightly greater acromiohumeral distance.
ePosters will be available shortly before Congress
Abstract
Background
Given the growing concerns regarding objective measures of clinical outcomes, attention has recently been devoted to the establishment of clinically significant outcome (CSO) thresholds for patient-reported functional scores following rotator cuff surgery. This study aimed to retrospectively compare patient-reported outcome measurements (PROMs) and radiographic data between patients who underwent arthroscopic superior capsule reconstruction (ASCR) with and without the long head of biceps tendon (LHBT) augmentation.
Methods
Forty-three patients receiving ASCR between 2016 and 2020 were enrolled, including a biceps augmentation group (27) and a nonaugmentation group (16). PROMs of American Shoulder and Elbow Surgeons (ASES), Constant score, Single Assessment Numeric Evaluation (SANE), and visual analog scale (VAS) scores and radiographic data including magnetic resonance imaging (MRI) and plain radiographs were collected and compared between the two groups. Anchor questions in CSO analysis for deriving the minimal clinically importance difference (MCID), substantial clinical benefit (SCB), patient acceptable symptom state (PASS), and maximal outcome improvement (MOI) values were applied at a minimum of 2 years postoperatively.
Results
Intergroup comparison based on patients’ satisfaction and perception of change or improvement exhibited significant differences in all 4 functional scores except for no significant difference in the △VAS scores. CSO analyses showed no significant difference in the percentage of patients achieving MCID, SCB, and PASS thresholds for the △ASES, △Constant, and △SANE scores between the two groups. A significant difference was found in the percentage of patients achieving the MOI for △ASES score with 70.4% in the augmented group and 37.5% in the non-augmented group respectively while the differences regarding the △Constant and △SANE scores were insignificant. The mean acromiohumeral distance (AHD) differed significantly between augmentation (8.1 ± 2.2 mm) and nonaugmentation (7 ± 1.9 mm) groups. The graft tear rate did not differ significantly.
Conclusion
There was no significant difference in patient-reported outcomes and percentage of patients achieving MCID, SCB, and PASS between isolated and augmented SCR groups. A higher percentage of patients achieving MOI and slightly greater AHD were found in the augmented group. Further evaluation is required to determine if there is any long-term benefit to LHBT augmentation of SCR.